Eylea: adverse event reports filed with FDA

25,826

reports as suspect product

0.1% of all reports · about 1,792 a year

968

reports, 12 months to June 2026

1,236 in the 12 months before

81.5%

marked serious by the reporter

87.6% across the class

33.6%

record death among outcomes, as reported

8,666 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Eylea reports recording the termmedian drug in vascular endothelial growth factor inhibitor

1. Deaththe patient died; cause not stated by this term31%8,006
2. Visual impairmentreduced vision7%1,811
3. Blindnessloss of sight5.2%1,349
4. Endophthalmitisinfection inside the eye4.7%1,210
5. Product dose omission issuea dose was missed4.2%1,081
6. Eye paineye pain4.1%1,054
7. Visual acuity reducedreduced sharpness of vision4%1,045
8. Blindness unilateral3.9%1,015
9. Vision blurredblurred vision3.9%1,004
10. Blindness transient3.7%966
11. Drug ineffectivethe medicine did not work as expected3.7%958
12. Off label useused for a purpose or in a way not on the label3.6%930
13. Eye inflammation3.2%828
14. Eye haemorrhage3%781
15. Vitreous floatersfloaters in vision2.6%683
16. Intraocular pressure increasedraised pressure in the eye2.5%643
17. Retinal haemorrhage1.9%493
18. Cataractclouding of the eye lens1.8%472
19. Non-infectious endophthalmitis1.6%413
20. Ocular hyperaemiaa red eye1.4%361
21. Vitritis1.3%336
22. Hospitalisationadmission to hospital1.3%324
23. Headachehead pain1.2%322
24. Injection site painpain where the injection was given1.2%317
25. Cerebrovascular accidentstroke1.2%314
26. Eye disorder1.2%313
27. Uveitis1.2%312
28. Product use issuea problem in how the product was used1.2%301
29. Wrong technique in product usage processthe product was used in the wrong way1.1%275
30. Vitrectomy1%267

Top 30 of 998 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 10 drugs in the vascular endothelial growth factor inhibitor class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 176,429 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 62.3% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 25,826 reports.

Drugs most often listed in the same reports

Other products listed in reports where Eylea is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the vascular endothelial growth factor inhibitor class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Eylea as a suspect or interacting product; reports listing it only as a concomitant medication (1,355) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.